Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zealand Pharma (ZLDPF)
OTHER OTC:ZLDPF
Holding ZLDPF?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.59Last Year’s EPS
-0.61Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 15, 2018
|% Change Since: -20.62%
|Next Earnings Date:Aug 16, 2018
Earnings Call Sentiment|Neutral
The earnings call reflects a balanced outlook with significant progress in clinical trials and a strong financial position, but also facing challenges with regulatory issues and increased operating costs.Company Guidance
During the Q3 2024 earnings call, Zealand Pharma provided guidance on various metrics and forward-looking statements. The company reported revenue of DKK 54 million for the first nine months, driven primarily by a license agreement with Novo Nordisk. Operating expenses totaled DKK 919 million, with research and development comprising 72% of these expenses, reflecting the company's focus on advancing its obesity pipeline. The CFO, Henriette Wennicke, highlighted a strong cash position of DKK 9.2 billion as of September 30, 2024, following capital raises and disbursements. Zealand Pharma maintained its guidance for net operating expenses between DKK 1.25 billion and DKK 1.35 billion for the year. The company expressed optimism about its obesity programs, particularly petrelintide, which aims to achieve GLP-1-like weight loss of 15% to 20% in longer-term trials while improving gastrointestinal tolerability. Denmark-based Zealand Pharma also anticipates initiating multiple Phase IIb trials in 2025 and continues to seek co-development and co-commercialization partnerships to maximize their market potential.Positive Results for Petrelintide Phase I Trial
Detailed data from the 16-week Phase I trial presented at ObesityWeek showed that petrelintide, a long-acting amylin analog, is well-tolerated with potential for better patient experience compared to GLP-1-based therapies, targeting 15%-20% weight loss in longer-term trials.
Strong Financial Position
Secured DKK 8.6 billion through capital raises and loan facility from the European Investment Bank, with cash and equivalents totaling DKK 9.2 billion as of September 30, 2024.
Encouraging Dapiglutide Phase Ib Trial Data
Reported positive top-line data from Part 1 of the Phase Ib trial for dapiglutide, a GLP-1/GLP-2 dual agonist, with plans to progress into a Phase IIb trial in 2025.
Boehringer Ingelheim Collaboration Success
Initiation of a large global Phase III program for survodutide in MASH and receiving U.S. FDA breakthrough therapy designation for treatment of adults with non-cirrhotic MASH.
---
ZLDPF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZLDPF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $125.31 | $119.04 | -5.00% |
| Aug 15, 2024 | $137.00 | $136.99 | >-0.01% |
| May 16, 2024 | $95.30 | $91.15 | -4.35% |
| Feb 27, 2024 | $103.00 | $90.00 | -12.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zealand Pharma (ZLDPF) report earnings?
Zealand Pharma (ZLDPF) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Zealand Pharma (ZLDPF) earnings time?
Zealand Pharma (ZLDPF) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZLDPF EPS forecast?
ZLDPF EPS forecast for the fiscal quarter 2024 (Q4) is -0.59.
---